[The effect of a combination of ridazolol and molsidomine on hemodynamics and left ventricular function in dilated cardiomyopathy].

Abstract

Haemodynamics and Left Ventricular Function in Patients with Dilated Cardiomyopathy after a Combination of Ridazolol and Molsidomine. To evaluate the haemodynamic properties of the new beta-blocker ridazolol alone and in combination with the vasodilator molsidomine a randomized study was carried out in 12 patients with dilated cardiomyopathy (NYHA II/III). beta-Blockade leads to a decreasing tendency in blood pressure and heart rate. Pulmonary capillary wedge pressure (PC) was not significantly altered and ejection fraction remained unchanged. Molsidomine showed a decrease of PC. The combination of both drugs revealed both the positive haemodynamic effects of molsidomine and the reduced heart rate of beta-blockade. Negative side effects could not be observed.

• Authors: W Haerer, E Henze, M Stauch
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 39 Issue 6 Pg. 714-6 (Jun 1989) ISSN: 0004-4172 [Print] Germany
• Vernacular Title: Einfluss einer Kombination von Ridazolol und Molsidomin auf Hämodynamik und linksventrikuläre Funktion bei dilatativer Kardiomyopathie.
• PMID: 2570582 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic beta-Antagonists
• Pyridazines
• ridazolol
• Molsidomine

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Adult
• Blood Pressure (drug effects)
• Cardiomyopathy, Dilated (drug therapy, physiopathology)
• Drug Therapy, Combination
• Hemodynamics (drug effects)
• Humans
• Molsidomine (administration & dosage, therapeutic use)
• Pyridazines (administration & dosage, therapeutic use)
• Random Allocation